Dietary Glutamic Acid Linked to Lower Risk of Colorectal Cancer

This article originally appeared here.
Share this content:
Dietary Glutamic Acid Linked to Lower Risk of Colorectal Cancer
Dietary Glutamic Acid Linked to Lower Risk of Colorectal Cancer

THURSDAY, Jan. 7, 2016 (HealthDay News) -- Dietary glutamic acid intake is associated with reduced risk of developing colorectal cancer (CRC), according to a study published online Dec. 30 in Cancer.

Gilson G. Viana Veloso, M.D., from the Erasmus Medical Center in Rotterdam, Netherlands, and colleagues examined the correlation between dietary glutamic acid intake with CRC risk, and whether the correlation was modified by body mass index (BMI). The study was embedded in the Rotterdam study, which included a prospective cohort of 5,362 adults aged 55 years or older.

The researchers found that 242 subjects developed CRC during follow-up. There was a significant correlation between baseline dietary glutamic acid intake with lower risk of developing CRC (hazard ratio per percent increase in glutamic acid of protein, 0.78; 95 percent confidence interval, 0.62 to 0.99). The risk reduction for CRC by dietary glutamic acid was significant for participants with a BMI of ≤25 kg/m² after stratification by BMI (hazard ratio per percent increase in glutamic acid of protein, 0.58; 95 percent confidence interval, 0.40 to 0.85); no correlation was seen for participants with BMI >25 kg/m² (hazard ratio per percent increase in glutamic acid of protein, 0.97; 95 percent confidence interval, 0.73 to 1.31).

"Our data suggest that baseline dietary glutamic acid intake is associated with a lower risk of developing CRC, but this association may be mainly present in non-overweight subjects," the authors write.

Several authors disclosed financial ties to the nutrition and insurance industries.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Improved achievement of glycemic targets, reduced body weight

European, American Guidelines Lead to Different Recs for Statins

European, American Guidelines Lead to Different Recs for ...

Quantification of CAC score can improve stratification for those at high, low risk for events

Hyperbaric O2 Therapy Effective in Maxillary Osteoradionecrosis

Hyperbaric O<sub>2</sub> Therapy Effective in Maxillary Osteoradionecrosis

Positive clinical outcome with HBOT for 85.7 percent of patients with maxillary bone osteoradionecrosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »